New NMD4C Collaborative Research Training Awards Launching May 2025
The NMD4C is excited to announce a new program for neuromuscular research trainees that will support collaboration opportunities between Canadian research labs! The NMD4C Collaborative Research Training Award program will provide funding awards of $2000 for research trainees to visit another neuromuscular lab within Canada to work on a collaborative research project while gaining hands-on experience, learning new techniques, and further developing their expertise in neuromuscular disease-focused research.
Mark your calendars – the program will launch on May 6, 2025, and will accept applications until June 15, 2025.
Stay tuned for more details on the application process and guidelines. We look forward to supporting the innovative research and professional growth of our trainees through this exciting new program!
Read next...
Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG
Nov 25-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!
2026 Awards Now Open for Nominations!
We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.
A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada
Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.